Wearable Skin Sensors to Assess Nocturnal Scratch Behavior
NCT ID: NCT03770858
Last Updated: 2023-10-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
23 participants
OBSERVATIONAL
2019-04-18
2022-08-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis
NCT05200403
Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults
NCT01232985
A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)
NCT05235724
Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis
NCT03233529
Scratch and Sleep Quantification in Atopic Dermatitis
NCT03490877
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Crisaborole and wearable sensor
Subjects will apply topical crisaborole twice daily to the affected atopic dermatitis areas for three weeks.
Crisaborole
Subject to apply topical crisaborole twice daily to the affected atopic dermatitis areas
Scratch sensor
advanced, flexible and wearable skin sensor
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Crisaborole
Subject to apply topical crisaborole twice daily to the affected atopic dermatitis areas
Scratch sensor
advanced, flexible and wearable skin sensor
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Systemic therapy use (e.g. oral corticosteroid, cyclosporine, methotrexate, phototherapy) within 28 days of subject enrollment
* Topical corticosteroid use or topical calcineurin inhibitor use within 14 days of subject enrollment
* Willingness and ability to set up an infrared video camera nightly
* Willing to apply topical crisaborole twice daily to affected atopic dermatitis areas of the body
Exclusion Criteria
* Inability to operate a smartphone or video camera
* Active atopic dermatitis on he dorsum of the hand or suprasternal notch
2 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Northwestern University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shuai (Steve) Xu
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shuai Xu
Role: PRINCIPAL_INVESTIGATOR
Northwestern University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Northwestern University
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
052018SX
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.